Dose-Sparing Efficacy of d-Limonene with Low-Dose Allopurinol in a Dual Model of Hyperuricemia and Gouty Arthritis in Rats
Nutrients · 2025
DOI: 10.3390/nu18010072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrients, 2025. Verfasst von Krishnaraju Venkatesan und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia. Hauptthemen laut MEDLINE: Arthritis, Gouty, Limonene, Allopurinol, Hyperuricemia. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deanship of Scientific Research at King Khalid University.
Abstract (Originalsprache)
Background: d-Limonene (LIM) is a food-derived monoterpenoid phytocompound predominantly found in citrus peels, endowed with potent antioxidant and anti-inflammatory properties, and has been reported to inhibit xanthine oxidase (XO) activity in vitro. This study investigated the dose-sparing efficacy of this dietary bioactive compound in combination with low-dose allopurinol (ALP) using a dual rat model combining potassium oxonate (PO)-induced hyperuricemia and monosodium urate (MSU)-triggered gouty arthritis, thereby capturing both metabolic and inflammatory dimensions of gout.
Methods
Female Wistar rats were PO-primed and MSU-challenged, then treated with LIM (50 mg/kg), ALP (5 or 10 mg/kg), or LIM + ALP. Outcomes included paw thickness, dysfunction and inflammation indices, serum uric acid, urea, creatinine, AST/ALT, cytokines (IL-1β, TNF-α, IL-6), oxidative stress markers (MDA, SOD, catalase, GSH), and NLRP3 immunoreactivity, supported by radiographic and histopathological analyses. Data were analyzed by one-way ANOVA with Tukey’s post hoc test.
Results
LIM improved clinical and biochemical outcomes versus monotherapies. However, LIM + low-dose ALP exhibited the greatest overall efficacy. On Day 30, paw thickness was significantly lower with LIM + ALP than with LIM alone (3.25 ± 0.31 vs. 3.98 ± 0.72 mm; p < 0.001). Serum uric acid and hepatic transaminases declined most with the combination (p < 0.0001 vs. LIM), accompanied by improved renal indices (p < 0.001). Pro-inflammatory cytokines were markedly reduced, NLRP3 immunostaining was minimal, and oxidative balance shifted toward homeostasis (↓ MDA; ↑ SOD, catalase, GSH). Radiographic and histological evaluations corroborated attenuation of joint inflammation and tissue damage.
Conclusions
In the PO + MSU gout model, co-administration of the food-derived compound LIM with low-dose ALP achieved additive, dose-sparing benefits across metabolic, inflammatory, and histological endpoints. While in vivo XO activity was not directly assessed, the findings are consistent with XO-pathway modulation, NLRP3–IL-1β suppression, and redox restoration. These results highlight the potential of dietary bioactives such as d-Limonene to complement standard urate-lowering therapy, warranting further pharmacokinetic and safety validation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia.
- Undergraduate Program, PSG College of Pharmacy, Peelamedu, Coimbatore 641004, India.
- Department of Pharmaceutics, College of Pharmacy, Jazan University, Jizan 45142, Saudi Arabia.
- Department of Pharmacology, Swamy Vivekanadha College of Pharmacy, Elayampalayam, Nammakkal 637205, India.
- Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
- Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
ORCID-Profile: Yahya I Asiri, Nizar Sirag, Hassabelrasoul Elfadil, Mahmoud Elodemi, Premalatha Paulsamy, Kumarappan Chidambaram
Förderung
- Deanship of Scientific Research at King Khalid University
Zitieren
APA
Venkatesan, K., Muralidharan, P., Sivadasan, D., Pichaivel, M., Asiri, Y. I., Asseri, K. A., Sirag, N., Elfadil, H., Elodemi, M., Prabahar, K., Paulsamy, P., & Chidambaram, K. (2025). Dose-Sparing Efficacy of d-Limonene with Low-Dose Allopurinol in a Dual Model of Hyperuricemia and Gouty Arthritis in Rats. Nutrients. https://doi.org/10.3390/nu18010072
Vancouver
Venkatesan K, Muralidharan P, Sivadasan D, Pichaivel M, Asiri YI, Asseri KA, et al. Dose-Sparing Efficacy of d-Limonene with Low-Dose Allopurinol in a Dual Model of Hyperuricemia and Gouty Arthritis in Rats. Nutrients. 2025. doi:10.3390/nu18010072
BibTeX
@article{Venkatesan2025,
author = {Venkatesan, Krishnaraju and Muralidharan, Pooja and Sivadasan, Durgaramani and Pichaivel, Manimekalai and Asiri, Yahya I and Asseri, Khalid A and Sirag, Nizar and Elfadil, Hassabelrasoul and Elodemi, Mahmoud and Prabahar, Kousalya and Paulsamy, Premalatha and Chidambaram, Kumarappan},
title = {Dose-Sparing Efficacy of d-Limonene with Low-Dose Allopurinol in a Dual Model of Hyperuricemia and Gouty Arthritis in Rats},
journal = {Nutrients},
year = {2025},
doi = {10.3390/nu18010072}
}
EUVIMED